Inavolisib

A new three-drug therapy, including palbociclib, inavolisib, and fulvestrant, significantly extends progression-free survival in HR+/HER2- breast cancer patients, with 46.2% showing no progression after 18 months, compared to 21.1% in the placebo group.

A three-drug therapy for advanced breast cancer, including inavolisib, palbociclib, and fulvestrant, delays disease progression by 15 months, compared to 7.3 months with palbociclib and fulvestrant alone, according to the INAVO120 study. The new combination has been FDA-approved and aims to become the standard of care for HR+, HER2- breast cancer.

A three-drug therapy (inavolisib, palbociclib, and fulvestrant) for PIK3CA-mutated HR+/HER2- breast cancer showed a 15-month delay in disease progression vs. 7.3 months with placebo, potentially doubling progression-free survival. The study, INAVO120, involved 325 patients across 28 countries, with 46.2% showing no progression after 18 months in the treatment group compared to 21.1% in the placebo group.

A three-drug treatment for advanced breast cancer delays disease progression by 15 months, twice the time of existing therapies, according to a trial involving 325 patients from 28 countries. The combination, including a new drug inavolisib, was found to be more effective than current NHS treatments, potentially transforming outcomes for those with PIK3CA-mutated HR+/HER2- breast cancer.

A three-drug therapy, including palbociclib, inavolisib, and fulvestrant, significantly delays progression of HR+/HER2- breast cancer by 15 months, compared to 7.3 months with a placebo.

A trial found that a combination of three drugs can double survival time for patients with incurable breast cancer, potentially transforming outcomes for many of the 61,000 UK women with advanced breast cancer.

A three-drug therapy for advanced breast cancer potentially doubles time without disease progression, according to a trial published in The New England Journal of Medicine. The combination, including palbociclib, inavolisib, and fulvestrant, delayed progression by 15 months compared to 7.3 months with a placebo. This breakthrough could be transformative for HR+/HER2- breast cancer patients.

A study led by Prof. Nick Turner at the Institute of Cancer Research demonstrates the potential of a three-drug therapy (inavolisib, palbociclib, and fulvestrant) to significantly improve progression-free survival in HR-positive breast cancer with PIK3CA mutations. The combination, already approved by the US FDA, could represent a transformative advance for patients.

October 2024 saw 4 new FDA cancer drug approvals: asciminib for CML, zolbetuximab-clzb for CLDN18.2-positive gastric/GEJ adenocarcinoma, inavolisib plus palbociclib/fulvestrant for PIK3CA-mutant HR+/HER2- breast cancer, and neoadjuvant/adjuvant nivolumab for NSCLC without EGFR/ALK mutations.

Courtney Van Houzen, PharmD, discusses bringing bispecific antibody treatments to community settings, inspired by a patient's need for continuity of care. Promising efficacy and safety of fianlimab and cemiplimab in advanced melanoma is highlighted. Inavolisib plus palbociclib and fulvestrant gains FDA approval for HR+/HER2- PIK3CA-mutated breast cancer. Talazoparib plus enzalutamide shows survival improvement in mCRPC. The TWINPEAK trial initiates with PT886 and pembrolizumab for gastric and GEJ cancers.